News
Why ASML Holding Stock Was Climbing Today
Shares of ASML Holdings (NASDAQ: ASML), the world's largest provider of semiconductor manufacturing equipment, were moving higher today. They were buoyed by an analyst upgrade last night, news that
Pfizer (PFE) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q2 2024 Earnings CallJul 30, 2024, 10:30 a.m. ET
Operator
Source Fool.com
Merck (MRK) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q2 2024 Earnings CallJul 30, 2024, 9:00 a.m. ET
Operator
Source Fool.com
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
If you're looking to pick up some exposure to biotechs that are developing anti-obesity medications, there's no shortage of options. But with the substantial risk of investing in biotech in general
Is AT&T's Nearly 6%-Yielding Dividend Finally Safe?
AT&T (NYSE: T) has one of the highest dividend yields in the S&P 500. At nearly 6%, it's a lot higher than the market index's average of 1.3%. Sustainability concerns are a big driver of that high
EQS-News: Biotest increases sales in the first half of 2024 by 35% to Euro 372 million
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
Viking Therapeutics (NASDAQ: VKTX) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the
Prediction: This Will Be Pfizer's Next Big Move
Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen (NASDAQ: BIIB) built itself into a multiple sclerosis (MS) treatment giant over the years -- but as older blockbusters lost exclusivity, growth stalled. And last year, annual revenue dropped
AT&T Shares Climb on Subscriber Additions. Should Investors Add the Stock to Their Portfolios?
Share prices of AT&T (NYSE: T) were heading nicely higher after the wireless company saw solid subscriber additions and generated strong free cash flow when it reported its second-quarter results
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't
Is Viking Therapeutics a Millionaire-Maker Stock?
Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new
3 Surprisingly Underrated Stocks to Buy Right Now
The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely.
Three Motley Fool contributors think
EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Investors looking for stocks that can go up want to turn their heads toward the medical technology industry. Demand for devices that enable minimally invasive surgical procedures and remote
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and
Why AbbVie Stock Was Cruising Higher on Thursday
AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AbbVie (NYSE: ABBV)Q2 2024 Earnings CallJul 25, 2024, 9:00 a.m. ET
Operator
Source Fool.com
Why Viking Therapeutics Stock Is Skyrocketing Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q2 2024 Earnings CallJul 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed
Is AbbVie the Best Dividend Stock for You?
It was great while it lasted, but AbbVie's (NYSE: ABBV) most important cash cow -- rheumatoid arthritis treatment Humira -- has been out of patent exclusivity in the U.S. since last year. That's not
AT&T Impresses With Subscriber Growth and Free Cash Flow
Coming a few days after a mixed earnings report from rival Verizon Communications, AT&T's (NYSE: T) second-quarter report suffered from a similar problem. Wireless customers have been slow to
3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years
If you're looking for some good dividend stocks to own in retirement, one thing you'll want to focus on is stability. Striking a balance between safety and dividend income can be key to ensuring you